Investors may wish to note that the President of Sera Prognostics, Inc., Evguenia Lindgardt, recently netted US$67k from selling stock, receiving an average price of US$3.15. On the bright side, that's just a small sale and only reduced their holding by 8.5%.
The Last 12 Months Of Insider Transactions At Sera Prognostics
Notably, that recent sale by President Evguenia Lindgardt was not the only time they sold Sera Prognostics shares this year. They previously made an even bigger sale of -US$194k worth of shares at a price of US$7.41 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$3.07. So it is hard to draw any strong conclusion from it.
Insiders in Sera Prognostics didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
Check out our latest analysis for Sera Prognostics
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
Does Sera Prognostics Boast High Insider Ownership?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Based on our data, Sera Prognostics insiders have about 4.3% of the stock, worth approximately US$5.0m. We consider this fairly low insider ownership.
So What Do The Sera Prognostics Insider Transactions Indicate?
Insiders haven't bought Sera Prognostics stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. We'd certainly practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that Sera Prognostics has 4 warning signs (2 are a bit concerning!) that deserve your attention before going any further with your analysis.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:SERA
Sera Prognostics
A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
Flawless balance sheet with slight risk.
Market Insights
Community Narratives



